ARCT NASDAQ
Arcturus Therapeutics Holdings Inc.
1W: -5.9%
1M: -22.2%
3M: +77.3%
YTD: +108.5%
1Y: -36.4%
3Y: -52.1%
5Y: -74.3%
$13.03
-0.18 (-1.36%)
Weekly Expected Move ±10.8%
$10
$12
$13
$14
$16
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (59)
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Arcturus raised to Buy at Citi after mid-stage trial data for liver disease drug
Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency
10 small-cap healthcare stocks with the strongest momentum grades
56,895 Shares in Arcturus Therapeutics Holdings Inc. $ARCT Bought by Hsbc Holdings PLC
BlackRock Inc. Invests $17.57 Million in Arcturus Therapeutics Holdings Inc. $ARCT
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
Dimensional Fund Advisors LP Decreases Holdings in Arcturus Therapeutics Holdings Inc. $ARCT
HC Wainwright Issues Positive Forecast for ARCT Earnings
Arcturus (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates
Exelixis (EXEL) Tops Q2 Earnings Estimates
PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $24.25 Consensus Target Price from Analysts
Amova Asset Management Americas Inc. Grows Stock Holdings in Arcturus Therapeutics Holdings Inc. $ARCT
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
Arcturus (ARCT) Q1 2026 Earnings Call Transcript
Arcturus outlines 12-week ARCT-032 Phase II enrollment and extends cash runway beyond Q2 2028
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
12 Health Care Stocks Moving In Thursday's After-Market Session
Here are the major earnings after the close Thursday
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200 Day Moving Average – Time to Sell?
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $29.50
Cathie Wood's ARK boosts Palantir, Tesla, Roninhood bets; cuts semiconductor exposure
Cathie Wood's weekly moves signal shift to AI, precision medicine
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200 Day Moving Average – Should You Sell?
Cathie Wood's Ark Invest in broad sell-off; trims AI, crypto, internet names
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $29.50 Average Target Price from Brokerages
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
HC Wainwright Issues Pessimistic Outlook for ARCT Earnings
ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT
Arcturus Therapeutics Holdings Inc. $ARCT Shares Purchased by Amova Asset Management Americas Inc.
Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026
Arcturus (ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics GAAP EPS of -$2.40 misses by $0.24, revenue of $82M misses by $8.47M
Arcturus Therapeutics Q4 Earnings Assessment
Here are the major earnings after the close Tuesday
Earnings Scheduled For March 3, 2026
Arcturus Therapeutics Q4 2025 Earnings Preview
Earnings Preview: Arcturus Therapeutics
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving Average – Should You Sell?
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Arcturus Therapeutics to Attend Upcoming Investor Conference